Government awards Murdoch $1.25m for drugs research December 6, 2016 Researchers at Murdoch University have been awarded $1.25million in government funding to help reduce the number of people who experience adverse drug reactions (ADR). Professor Elizabeth Phillips, Director of the Centre for Clinical Pharmacology and Infectious Diseases at IIID ADRs present a considerable strain on healthcare providers around the world, accounting for about 6 per cent of in-patient hospital admissions at an annual cost of $136 billion. Murdoch University’s Institute for Immunology and Infectious Diseases (IIID) aims to translate these findings into ways of significantly reducing the burden of ADRs through prediction and prevention. The Australian Government’s National Health and Medical Research Council (NHMRC) have awarded $1.25 million in funding for the four year study. Professor Elizabeth Phillips, Director of the Centre for Clinical Pharmacology and Infectious Diseases at IIID, will lead the project as Chief Investigator. She said: “Serious and life-threatening immunologically-mediated ADRs are driven largely by genetic factors and present both a physical and financial burden to patients, families and healthcare services around the world. “Short-term, there is a significant risk of death and infectious complications; long-term, patients may suffer blindness, digestive, respiratory and reproductive complications, depression, anxiety, fear of taking drugs and shortened life-span. “This funding will be used to develop a strategy which improves drug safety and guides ways to reduce ADRs, both to the individual patient and through safer drug design and development.” The research team at IIID aims to provide strategies to predict which specific drugs are more likely to cause ADRs before they are approved for use in humans. They are following important leads which suggest that the clue to why some patients carrying specific genetic risk factors develop severe immunologically-mediated ADRs lies in specific cellular and molecular signatures present in the skin of those affected. The team expects these findings to translate into the development of sensitive and predictive blood tests that could detect the same molecular signatures they have found in the skin of diseased patients in the blood of patients before they take a drug. This will represent an important breakthrough to determine which of the small fraction of patients carrying a genetic risk factor will develop a severe ADR. Murdoch University was also successful in another seven NHMRC projects in collaboration with teams at other universities. Dr David Palmer is a Senior Lecturer in the School of Arts and will take part in a $1.5m study which will examine a minimally invasive approach to managing early childhood dental health in Aboriginal pre-schoolers. Professor Rhonda Marriott is Chair of Nursing, Maternal and New Born Health, Aboriginal Health and Wellbeing at the School of Psychology and Exercise Science. She is contributing to two NHMRC projects. A $1.3m study to validate a screening tool for anxiety and depression in Aboriginal perinatal women, particularly in remote areas. A $1.1m research project which will identify and quantify the links between stillbirths and deaths across regions and cultural groups, particularly Aboriginal and Torres Strait Islander Australians. Associate Professor Robert Trengove, from Murdoch University’s Separation Science and Metabolomics Laboratory, is a Chief Investigator on a $1m project to identify biomarkers to define treatment for cystic fibrosis. Adjunct Professor Dr David Nolan, at IIID, is part of a $900,000 study of the risk factors for long term chronic disease events in HIV-positive patients. Associate Professor Mark Watson, Director of Laboratory Services at IIID, will take part in an $850,000 project on cancer immunology analysis of T-cell responses in thoracic malignancies. Professor Bruce Gardiner, Deputy Dean at the School of Engineering and Information Technology, is part of an $800,000 study which will develop a method to monitor the kidney during surgery. The grant will fund a two year postdoctoral course at Murdoch to perform mathematical modelling of the oxygen transport in the kidney. Professor Stephen Wilton, Foundation Chair in Molecular Therapies at the Centre for Comparative Genomics, will join a research team who will study cellular shedding as therapeutic targets in diabetes and cardiovascular disease. Dr Katie Attwell, from the Sir Walter Murdoch School of Public Policy and International Affairs, is an Associate Investigator on a three year project which received almost $750,000 to determine the drivers of vaccine rejection. Professor David Morrison, Murdoch University Deputy Vice Chancellor Research & Innovation, said: “This funding award from the Australian Government recognises the high quality research carried out here at Murdoch University. “I’m immensely proud of our researchers and the work they’re doing to meet the challenges facing the world we live in.” Print This Post Media contact: Thomas Smith Tel: 08 9360 6742 | Mobile: 0431 165 231 | Email: email@example.com Categories: General Tags: adr, adverse drug reactions, associate professor mark watson, centre for comparative genomics, dr david nolan, iiid, nhmrc, professor bruce gardiner, professor david morrison, professor elizabeth phillips, professor rhonda marriott, professor robert trengove, professor stephen wilton, research & innovation, separation science laboratory Comments (One response) Andrew Taggart December 8, 2016 Well done to all researchers Murdoch is committed to solving some of the worlds most wicked problems A good sample funded here. Leave a comment Name (required) Mail (will not be published) (required) Website You can use these tags : <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong> We read every comment and will make every effort to approve each new comment within one working day. To ensure speedy posting, please keep your comments relevant to the topic of discussion, free of inappropriate language and in-line with the editorial integrity of this newsroom. If not, your comments may not be published. Thanks for commenting!